GlassScriptPhysician profile
Michael Anthony Samel
NPI 1174291264
$1,357.62
in general payments reported to CMS, 2019-2025
20 companies · $307 in 2025
The $307 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $108 · 2023: $336 · 2024: $607 · 2025: $307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,249.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $309.63 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $160.91 | 2025 | Airsupra, Breztri |
| Lexicon Pharmaceuticals, INC. | $141.21 | 2024 | Inpefa |
| Lilly USA, LLC | $119.25 | 2024-2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.76 | 2022 | |
| Paratek Pharmaceuticals, INC. | $104.14 | 2024 | Nuzyra |
| Exact Sciences Corporation | $86.05 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Janssen Pharmaceuticals, INC | $45.17 | 2024 | Xarelto, Spravato |
| Ucb, INC. | $36.64 | 2024 | Cimzia, Briviact |
| Abbvie INC. | $33.14 | 2023 | Vraylar, Ubrelvy |
| Sumitomo Pharma America, INC. | $28.99 | 2023 | Gemtesa |
| Alexion Pharmaceuticals, INC. | $28.89 | 2024 | Ultomiris |
| Amneal Pharmaceuticals LLC | $28.33 | 2025 | Crexont |
| Verona Pharma, INC. | $26.24 | 2025 | Ohtuvayre |
| Merck Sharp & Dohme LLC | $21.05 | 2023 | Bridion |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz Pharmaceuticals, LLC | $19.02 | 2025 | Inbrija |
| Amgen INC. | $17.44 | 2024 | Otezla |
| Emd Serono, INC. | $14.67 | 2023 | Mavenclad |
| Ibsa Pharma INC. | $14.64 | 2024 | Tirosint, Licart |
| Glaxosmithkline, LLC. | $14.45 | 2024 | Arexvy, Fluarix Quadrivalent, Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Samel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.